Exhibitor Events

Wheel of fortune where you can win promotional gifts (T-shirts, water bottles, cell phone chains, etc.) every day from 4 p.m. until the end of the trade fair. 
Anyone can take part in exchange for a business card. 

Plus, answer two questions correctly about a short film we show. The prizes will again be giveaways and visitors only need to leave us their business card to take part.

Dates: 12PM, Monday, June 3 – 4:30PM, Thursday, June 6 

BrevisRefero (Booth#1313 – brevisrefero.com), in partnership with the educational platform BrickMMO (brickmmo.com), will be showcasing an ‘Interactive Educational Biologics CDMO Facility Built Exclusively of LEGO® Bricks’ (sized 7ft x 2.5ft) featured at our booth. BIO attendees will be able to join us at our booth for an immersive and educational look at the biologics manufacturing like never before! With multimedia components in each room, and moving LEGO® systems simulating typical biomanufacturing processes, to learn more about each manufacturing suite and its role in the overall manufacturing process. Each CDMO facility room has been sponsored by an CDMO exhibiting at the BIO 2024 conference; Process Development Laboratory (Biodextris, Booth#4551) Upstream Manufacturing (JOINN Biologics, Booth#1115), Downstream Manufacturing (WheelerBio, Booth#4955), Quality Control Laboratory (Scorpius, Booth#4916), and Fill/Finish Manufacturing (Argonaut, Booth#5742). 

Our interactive CDMO facility is a unique, creative, and new way to increase engagement, connection, and impactful biologics learnings at BIO. With such a high presence of CDMO company booths at the BIO conference, along with planned activities to engage with our CDMO sponsor booths, we feel that our event will help to increase engagement with many CDMO booths and provide a better understanding and appreciation towards CDMO activities and biomanufacturing processes overall, that produce life-saving products every day.

Naoki Yamada, Ph.D., Director Strategy and Operations, FUJIFILM Pharmaceuticals U.S.A., Inc. is presenting on:  

Fujifilm Nanoparticle Solutions for Advanced Drug Development: Ionizable Lipids/LNP for Nucleic Acid and Liposome for Small Molecules 

• Ionized lipids are materials that have a significant impact on the efficacy and safety on nucleic acid delivery by lipid nanoparticles (LNPs). We will present applications of ionized lipids provided by Fujifilm for mRNA and pDNP delivery.
• Liposome is a formulation technology that improves the kinetics and safety of small molecules. This presentation will introduce Fujifilm's established liposome capabilities and the new possibilities of liposomes in the field of small molecule anticancer drug discovery.

Albert Zhang, Field Marketing & CRO Specialist, Wako Europe Laboratory Chemicals, and Hiroshi Nakajima, Bio One Stop Solutions Department, Laboratory Chemicals Sales Operations is presenting on: 

FUJIFILM Group Capabilities for Drug Discovery

FUJIFILM Wako Pure Chemicals business within the FUJIFILM Group
• CRO Services: Contract research services, such as AI-based drug discovery and h-iPS cell based assays, to the pharmaceutical and biotechnology industries and academic institutions
• Cell Products: We have teamed up with the National Institute of Biomedical Innovation in Japan to bring you access to over 1,600 cell lines as the exclusive provider

Keith R. Olson, Ph.D., Executive Vice President, Commercial Operations, FUJIFILM Cellular Dynamics is presenting on:

Leveraging Human iPSCs for Therapeutic and Drug Discovery Applications

• Provide context on the internal expertise and capabilities of Fujifilm FCDI w/ iPSC Material
• Discuss new product launches, particularly sensory neurons, and their applications in the market
• Discuss CDMO capabilities, capacity and expertise as a backdrop for working w/ FCDI as a partner"
"In Booth Presentation

Peter Dam Madsen, Senior Vice President Strategic Business Services, FUJIFILM Diosynth Biotechnologies is presenting on:

KojoX- Transforming the CDMO Industry to Improve patient Access to Medicine

•The need for medicine is increasing globally and existing capacity is unable to meet forecasted market demands.
•KojoX is a new level of global modularity that allows FDB to give our customers everything they need with one partner to develop and commercialize treatments and therapies effectively and efficiently to make patients’ lives better.
•Our KojoX network offers scalability solutions and unprecedented delivery through quality, convenience, flexibility and stability, enabling accelerated time to market and security of supply. 
•FDB are creating a future that delivers an ADC offering for our partners.

Robert Bukar, Vice President, FUJIFILM Wako Chemicals U.S.A. Corporation is presenting on:

Wako Automation, part of FUJIFILM Wako Chemicals U.S.A., an innovative laboratory automation integrator powered by Wako's Director Scheduling Software

• Use Director to integrate your laboratory instruments into a fully automated system, increasing the efficiency, reliability, and traceability of your process.
• Instrumentation companies can utilize Director as their own OEM scheduling software, expanding the capabilities of their instrument, while maintaining direct contact with their customers.
• Director's open API architecture and software development kit enables customers and partners to customize Director to your needs, providing the freedom to take control of your scheduling software, without being dependent on your software provider.

Maja Pedersen, Executive Vice President Global Quality and Chief Quality Officer, FUJIFILM Diosynth Biotechnologies is presenting on:

Proactive Leadership to Ensure Quality During Exponential Growth  

•Maintaining leadership in regulatory standards and compliance within the pharmaceutical and biotech industry is a multifaceted endeavour. This continuous process demands proactive strategies, strategic investments, and ongoing collaboration with regulatory agencies and industry partners.
•Through proactive engagement, strategic investments, and continuous improvement, FDB remains committed to ensuring that its operations meet the highest regulatory standards and that we support our people to instil a quality culture that permeates the organization.
•Leveraging advanced technologies to optimise processes, decision making and to anticipate future regulatory challenges ensures delivery of life-saving medicines worldwide.
 

Erik Vaessen, Ph.D., Chief Business Officer, Life Sciences, FUJIFILM Irvine Scientific will present on:

Learn how FUJIFILM Irvine Scientific supports your bioprocessing needs to make new therapies a reality 

FUJIFILM Irvine Scientific leverages our collective capabilities and responsiveness to best serve our partners, from small biotechs to the largest biopharmaceutical companies. 
• Collaboration with you to develop customized media solutions and technology services to achieve the desired product quality and quantity attributes
• Delivery of consistent quality, reliability, and sustainable manufacturing excellence for every step in a commercial therapy
• Operations with stringent global quality system, code of conduct, and ESG policies for ethical and responsible business practices to meet today’s supplier qualification environment

Ian Goodwin, Director of Program Design, FUJIFILM Diosynth Biotechnologies is presenting on:

Advancing Tomorrow’s Medicines Through Innovative Solutions

•Strategic innovation has been the core of Fujifilm’s success during the transition from photography to life sciences.
•Science moves fast, resulting in the development of novel therapies that offer incredible potential benefits to patients but these can only become reality if they can be produced consistently and economically.
•Anticipating future trends enables FDB to effectively manufacture new therapies and maintain our position as an Industry leader.
•The case study details the development of a flow electroporation device and its path to clinical reality."
 

Join us at our booth for an engaging showcase featuring a high-level overview of our company’s core business strengths and research, manufacturing, and commercialization capabilities. Discover our impressive biosimilar prowess and technical platforms through dynamic presentations. Meanwhile, we’ll highlight our innovative product and formulation development achievements, including strategic opportunities. Delve into the latest research outcomes and competitive advantages of our rising star, serplulimab, the world’s first anti-PD-1 mAb in small cell lung cancer, and explore the potential of our promising pipeline, including HLX22 (anti-HER2 mAb), HLX42 (EGFR ADC) and HLX43 (PD-L1 ADC). Network with Henlius team and industry peers at our reception as we chart the course for future advancements.

The PROMER-based miRNA detection method, which is an original technology already secured by NuriBio Co., Ltd., can sensitively and specifically detect miRNA in a very small amount of samples. 
As an event, we plan to provide a skin diagnosis miRNA analysis service that can diagnose various skin problems using a simple detection method.

Visit Albuquerque Representatives will be present to show attendees what it really feels like to visit New Mexico - with virtual reality! Come by our New Mexico Biosciences booth to learn more, and for a VR experience like none you have ever seen!